WO2006065711A3 - Antagonistes du recepteur de tachykinine d'octahydropyrano[3,4-c]pyrrole - Google Patents

Antagonistes du recepteur de tachykinine d'octahydropyrano[3,4-c]pyrrole Download PDF

Info

Publication number
WO2006065711A3
WO2006065711A3 PCT/US2005/044822 US2005044822W WO2006065711A3 WO 2006065711 A3 WO2006065711 A3 WO 2006065711A3 US 2005044822 W US2005044822 W US 2005044822W WO 2006065711 A3 WO2006065711 A3 WO 2006065711A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
octahydropyrano
pyrrole
compounds
tachykinin receptor
Prior art date
Application number
PCT/US2005/044822
Other languages
English (en)
Other versions
WO2006065711A2 (fr
Inventor
Robert J Devita
Jinlong Jiang
Sander G Mills
Jonathan R Young
Original Assignee
Merck & Co Inc
Robert J Devita
Jinlong Jiang
Sander G Mills
Jonathan R Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Robert J Devita, Jinlong Jiang, Sander G Mills, Jonathan R Young filed Critical Merck & Co Inc
Priority to CA002590039A priority Critical patent/CA2590039A1/fr
Priority to AU2005316676A priority patent/AU2005316676A1/en
Priority to JP2007546800A priority patent/JP2008523147A/ja
Priority to US11/792,514 priority patent/US7652058B2/en
Priority to EP05853689A priority patent/EP1827420A4/fr
Publication of WO2006065711A2 publication Critical patent/WO2006065711A2/fr
Publication of WO2006065711A3 publication Critical patent/WO2006065711A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention se rapporte à certains composés d'hydropyranopyrrolidine, utiles comme antagonistes du récepteur de la neurokinine-1 (NK-1) et comme inhibiteurs de la tachykinine, en particulier de la substance P. Cette invention concerne également des formulations pharmaceutiques comprenant ces composés comme ingrédients actifs ainsi que l'utilisation de ces composés et de leurs formulations dans le traitement de certains troubles, parmi lesquels figurent le vomissement, l'incontinence urinaire, la dépression et l'anxiété.
PCT/US2005/044822 2004-12-14 2005-12-12 Antagonistes du recepteur de tachykinine d'octahydropyrano[3,4-c]pyrrole WO2006065711A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002590039A CA2590039A1 (fr) 2004-12-14 2005-12-12 Antagonistes du recepteur de tachykinine d'octahydropyrano[3,4-c]pyrrole
AU2005316676A AU2005316676A1 (en) 2004-12-14 2005-12-12 Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists
JP2007546800A JP2008523147A (ja) 2004-12-14 2005-12-12 オクタヒドロピラノ［３，４−ｃ］ピロールタキキニン受容体拮抗薬
US11/792,514 US7652058B2 (en) 2004-12-14 2005-12-12 Octahydropyrano[3,4-C]pyrrole tachykinin receptor antagonists
EP05853689A EP1827420A4 (fr) 2004-12-14 2005-12-12 Antagonistes du recepteur de tachykinine d'octahydropyrano[3,4-c]pyrrole

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63577704P 2004-12-14 2004-12-14
US60/635,777 2004-12-14
US63806504P 2004-12-20 2004-12-20
US60/638,065 2004-12-20

Publications (2)

Publication Number Publication Date
WO2006065711A2 WO2006065711A2 (fr) 2006-06-22
WO2006065711A3 true WO2006065711A3 (fr) 2006-08-31

Family

ID=36588419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044822 WO2006065711A2 (fr) 2004-12-14 2005-12-12 Antagonistes du recepteur de tachykinine d'octahydropyrano[3,4-c]pyrrole

Country Status (6)

Country Link
US (1) US7652058B2 (fr)
EP (1) EP1827420A4 (fr)
JP (1) JP2008523147A (fr)
AU (1) AU2005316676A1 (fr)
CA (1) CA2590039A1 (fr)
WO (1) WO2006065711A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075528A2 (fr) * 2005-12-22 2007-07-05 Merck & Co., Inc. Antagonistes de recepteur d’octahydropyrano[3,4-c]pyrrole-tachykinine
US8124633B2 (en) * 2007-04-10 2012-02-28 Merck Sharp & Dohme Corp. Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
WO2009002770A1 (fr) * 2007-06-22 2008-12-31 Merck & Co., Inc. Antagonistes 6,5-pyrrolopipéridine des récepteurs de tachykinine
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
MX2014010012A (es) * 2012-02-22 2014-09-12 Leo Pharma As Nuevos compuestos antagonistas del receptor de neurocinina 1.
EP3758688B1 (fr) 2018-02-26 2024-03-27 Ospedale San Raffaele S.r.l. Antagonistes nk-1 destinés à être utilisés dans le traitement de la douleur oculaire
EP3870572A1 (fr) * 2018-10-23 2021-09-01 Myelopro Diagnostics and Research GmbH Composés ciblant la calréticuline mutante
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535169A (en) * 1983-09-12 1985-08-13 The Board Of Trustees Of The University Of Illinois 5H-6-oxo-2,3,4,4a,7,7a-hexahydropyrano[2,3-b]pyrrole and the preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722883B2 (en) * 1995-10-18 2000-08-10 Merck & Co., Inc. Cyclopentyl tachykinin receptor antagonists
TWI341198B (en) * 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535169A (en) * 1983-09-12 1985-08-13 The Board Of Trustees Of The University Of Illinois 5H-6-oxo-2,3,4,4a,7,7a-hexahydropyrano[2,3-b]pyrrole and the preparation thereof

Also Published As

Publication number Publication date
AU2005316676A1 (en) 2006-06-22
EP1827420A2 (fr) 2007-09-05
US20080108689A1 (en) 2008-05-08
WO2006065711A2 (fr) 2006-06-22
EP1827420A4 (fr) 2009-03-04
CA2590039A1 (fr) 2006-06-22
JP2008523147A (ja) 2008-07-03
US7652058B2 (en) 2010-01-26

Similar Documents

Publication Publication Date Title
UA84192C2 (en) Hydroisoindoline tachykinin receptor antagonists
WO2006065711A3 (fr) Antagonistes du recepteur de tachykinine d'octahydropyrano[3,4-c]pyrrole
WO2005032464A3 (fr) Antagonistes du recepteur de la tachykinine a base de phenyle pyrrolidine ether
WO2006060346A3 (fr) Antagonistes du recepteur de tachykinine de 8-phenyl-5,6,7,8-hydroquinoline
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
EA200702044A1 (ru) Имидазопиридазиновые соединения
IL210071A (en) Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
WO2003087094A3 (fr) Nouveaux derives du pyrrolidinium
WO2005103050A3 (fr) Azaindoles utiles en tant qu'inhibiteurs de la proteine serine/threonine kinase superhelice de la famille rho (rock) et d'autres proteines kinases
WO2004108133A3 (fr) Modulateurs du recepteur vr1
WO2006002361A3 (fr) 2-methylpropanamides et leur utilisation comme produits pharmaceutiques
GEP20104962B (en) Fused heterocyclic compounds
WO2006070325A3 (fr) Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
WO2006034048A3 (fr) Agents therapeutiques ciblant le canal ncca-atp et procedes d'utilisation associes
WO2007002457A3 (fr) Antagonistes des recepteurs de tachykinine hydro-iso-indolique
WO2006044293A3 (fr) Composes bicycliques utilises comme antagonistes du recepteur d'hormone concentrant la melanine selectifs destines au traitement de l'obesite et de troubles associes
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
WO2004026836A8 (fr) Derives de 1-pyridin-4-yl-uree
WO2007081897A3 (fr) Antagonistes des récepteurs des tachykinines à noyaux triazoles fusionnés
WO2005030209A8 (fr) Derives de pyridine et leur utilisation comme antagonistes de l'urotensine ii
WO2007075528A3 (fr) Antagonistes de recepteur d’octahydropyrano[3,4-c]pyrrole-tachykinine
WO2006073589A3 (fr) Antagonistes des recepteurs de la tachykinine a base de cycloalkyl-ceto-piperidine
EP1879027A4 (fr) Agent de prévention et de traitement des pancréatites

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2317/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005316676

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11792514

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2590039

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005853689

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580042770.1

Country of ref document: CN

Ref document number: 2007546800

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005316676

Country of ref document: AU

Date of ref document: 20051212

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005316676

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005853689

Country of ref document: EP